Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination document

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination document

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination document
07 March 2013
(258.82 Kb 15 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 01 March 2013